Exegenesis Bio has received Orphan Drug Designation from the US FDA for EXG110, a novel gene therapy designed to treat Fabry disease. This designation supports the development of the treatment, which is currently undergoing clinical trials in China and plans to expand to the US.
Company Information
Company
Exegenesis Bio
Location
Philadelphia, Pennsylvania, United States
About
Exegenesis Bio is a clinical stage global gene therapy company focused on developing innovative treatments for rare diseases. Their flagship product, EXG110, aims to treat Fabry disease through a novel gene therapy approach. The company emphasizes its commitment to rigorous science and innovation in the field of gene therapy. Exegenesis Bio is also working on additional therapies targeting other conditions, such as wet Age-Related Macular Degeneration.
Fundz sees it the moment Exegenesis Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
PhiladelphiaBiotechnologyHealth CareGeneticsTherapeutics